1999
DOI: 10.1038/sj.jhh.1000880
|View full text |Cite
|
Sign up to set email alerts
|

Losartan: a study of pharmacovigilance data on 14 522 patients

Abstract: The objective of this study was to undertake a postmarketing safety surveillance study of losartan, the first specific angiotensin-II receptor antagonist to be marketed in England. It is a non-interventional observational cohort study using the technique of prescription-event monitoring. Subjects who took part in the study were from 14 522 patients treated by general practitioners in England. We recorded adverse drug reactions, adverse events, reasons for stopping the drug, pregnancies and deaths. The results … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
13
0
1

Year Published

2001
2001
2015
2015

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 31 publications
(14 citation statements)
references
References 5 publications
0
13
0
1
Order By: Relevance
“…11 The response rate for the losartan PEM study was similar at 54.6%. 12 The green forms were sent to the prescribers 6 months after the first prescription of valsartan; thus, a limitation of the study is the lack of capture of any events which occurred more than 6 months after the first prescription. This study is the largest safety study of valsartan so far reported (MEDLINE and EMBASE search criteria).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…11 The response rate for the losartan PEM study was similar at 54.6%. 12 The green forms were sent to the prescribers 6 months after the first prescription of valsartan; thus, a limitation of the study is the lack of capture of any events which occurred more than 6 months after the first prescription. This study is the largest safety study of valsartan so far reported (MEDLINE and EMBASE search criteria).…”
Section: Discussionmentioning
confidence: 99%
“…This is similar to the results with losartan (82.5%). 12 Also, it was said to have been effective in 84.8% of the 11 191 patients for whom the GPs gave an opinion regarding effectiveness.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Based on limited data from first trimester exposure (Walfisch et al 2011;Schaefer 2003;Gersak et al 2009;Serreau et al 2005;Chung et al 2001;Biswas et al 2002;Mann et al 1999), there does not appear to be an elevated risk of major congenital malformations above the risk in pregnant hypertensive women, untreated or treated with other medications.…”
Section: Angiotensin Ii-at1 Receptor Blockersmentioning
confidence: 91%
“…Nevertheless post marketing surveillance studies report 'dizziness' as one of the most common symptoms reported by patients taking these drugs. 5 The identification of an uncommon side effect of a drug requires clinical vigilance and clinicians should be aware of this possible adverse reaction to angiotensin receptor blocking drugs, particularly in view of their increasing use in the management of hypertension and heart failure. …”
mentioning
confidence: 99%